Prothrombin Gene Mutation Cost and Self-Pay Testing Options

Medical & affiliate disclosure: CTX Stat provides educational laboratory information and is not a substitute for professional medical advice, diagnosis, or treatment. CTX Stat may receive compensation from some outbound provider links when an affiliate program is active; provider comparisons and rankings are based on consumer fit, effective cost, access, policies, and reputation—not commission.

If you are comparing prothrombin gene mutation test cost, the most important number is not the headline price. It is the effective out-of-pocket price after required order fees, the lab network used, state restrictions, and whether the test is actually the Factor II/F2 G20210A mutation test rather than a routine prothrombin time test.

Prothrombin gene mutation test cost comparison

For this comparison, “total cost” means the consumer-facing test price plus required order or requisition charges when those are disclosed before checkout. Optional upgrades, coupon codes, insurance billing, and physician office visit costs are not included because they vary by person. Availability can change by state and by lab network, so confirm the final checkout total before paying.

Ordering route	Test/lab network	Advertised or listed price	Required fees found	Effective self-pay cost	Important availability notes
Ulta Lab Tests	Quest test 17909: Prothrombin (Factor II) 20210G>A Mutation Analysis	$168.95	$12.95 requisition charge per independent checkout comparison	$181.90	Blood draw through participating collection sites; comparison data lists NJ, NY, and RI restrictions. Ulta’s public test page describes blood draw collection, no preparation instructions, and average 4–5 business day processing.
LabsMD	Prothrombin (Factor II), listed as a self-order lab test	Public search listings show this test in the several-hundred-dollar range; a recent LabsMD listing showed $792, while independent comparison data has shown $709.	No separate mandatory fee was confirmed from the accessible public listing.	Confirm at checkout; likely substantially higher than the lowest confirmed option.	Independent comparison data has listed restrictions including NY, NJ, MA, MD, and RI for this Quest-based option. Treat the checkout page as the source of truth.
Private MD Labs	Quest or Labcorp collection depending on product and location	Product-level public pricing for this exact test was not consistently visible in accessible current pages; third-party comparison data has listed a $709 option.	Confirm in cart.	Not reliably confirmed from public product page	Private MD Labs says laboratory testing is available in 46 states and uses Quest or Labcorp collection centers; product-specific restrictions may still apply.
Your clinician orders through Labcorp	Labcorp test 511162: Factor II (Prothrombin), DNA Analysis	Not a fixed direct-to-consumer price on the test menu	Depends on insurance, self-pay estimate, and ordering setting	Variable	Requires an ordering provider. Labcorp lists CPT 81240, PCR/restriction enzyme methodology, and usual turnaround of 5–7 days.
Your clinician orders through Quest	Quest test 17909: Prothrombin Factor II 20210G>A Mutation Analysis	Not a fixed direct-to-consumer price on the test menu	Depends on insurance, self-pay estimate, and ordering setting	Variable	Requires an ordering clinician in standard channels. Quest’s thrombosis menu lists the test code, whole-blood EDTA specimen, and CPT 81240.

Key source notes: Ulta’s public test listing shows the Prothrombin (Factor II) 20210G>A Mutation Analysis at $168.95 and describes blood draw collection, no preparation instructions, and average 4–5 business day processing. An independent lab-price comparison page for Quest test 17909 itemizes Ulta’s $168.95 test price plus a $12.95 requisition charge for a $181.90 total and lists LabsMD and Private MD options at higher prices. Labcorp’s test directory identifies its Factor II DNA Analysis as test 511162 with CPT 81240, PCR-based methodology, and 5–7 day usual turnaround. Quest-associated directories identify Quest test 17909, CPT 81240, whole-blood EDTA collection, and a report time often listed around 3–4 days from receipt at the performing laboratory. See Ulta Lab Tests, , Labcorp test 511162, and the Quest bleeding and thrombosis test menu.

What is the prothrombin gene mutation test?

The prothrombin gene mutation test is a targeted genetic test for a variant in the F2 gene. The classic name is prothrombin G20210A. Current genetic nomenclature often calls it F2 c.*97G>A. The test is used in thrombophilia risk assessment, especially for venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism.

Prothrombin, also called coagulation factor II, is a protein involved in the clotting cascade. The G20210A variant is associated with increased prothrombin levels and a higher tendency toward venous clotting in some people. MedlinePlus Genetics describes prothrombin thrombophilia as a disorder that increases the risk of abnormal blood clots and notes that the variant is more common in people of European ancestry. GeneReviews emphasizes that thrombotic risk is multifactorial: genotype, family history, other thrombophilias, pregnancy, estrogen exposure, surgery, immobility, cancer, and other circumstances all matter.

It is not the same as PT/INR

The naming is confusing. A prothrombin time or PT/INR test measures how long plasma takes to clot. It is frequently used to monitor warfarin therapy or evaluate bleeding/clotting function. A prothrombin gene mutation test looks at DNA. A normal PT/INR does not rule out the F2 mutation, and a positive F2 mutation does not diagnose an active clot.

Test name you may see	What it measures	Use	Typical cost pattern
Prothrombin gene mutation, Factor II mutation, F2 G20210A, F2 c.*97G>A	Inherited DNA variant	Thrombophilia risk assessment	Often $180+ self-pay online; variable through insurance
PT, PT/INR, Prothrombin Time with INR	Clotting time	Warfarin monitoring, liver disease or bleeding evaluation, coagulation assessment	Usually much cheaper; not a genetic test
Thrombophilia panel	Multiple inherited and/or acquired clotting risk markers	Selected VTE evaluation when results may change care	Can cost hundreds to thousands depending on components

Who should consider prothrombin mutation testing?

Testing is most useful when the result could change a medical decision. The American College of Medical Genetics and Genomics technical standard describes factor V Leiden and factor II c.*97G>A as common genetic variants associated with VTE and states that testing may be appropriate in patients with VTE when results will influence treatment or management, and in selected asymptomatic relatives when results may guide prevention during higher-risk circumstances.

Examples where a clinician may consider testing include:

• a personal history of unprovoked or unusual-site venous thrombosis;
• VTE at a young age, especially with family history;
• a first-degree relative with a known F2 mutation when results would affect pregnancy, hormone, surgery, or travel planning;
• recurrent VTE or VTE with additional thrombophilia concerns;
• preconception, pregnancy, or postpartum planning in someone with a relevant clotting history or strong family history.

Not everyone with a clot needs inherited thrombophilia testing, and not everyone with a family history benefits from self-ordering. The American Society of Hematology thrombophilia testing guideline page notes that commonly tested hereditary thrombophilias include antithrombin, protein C, protein S deficiencies, factor V Leiden, and prothrombin G20210A, but testing decisions depend on the clinical scenario. If the result would not change treatment duration, pregnancy planning, hormone choices, or family counseling, testing may add cost without clear benefit.

Self-pay ordering options: how they work

1. Online self-pay service with clinician-authorized order

This is the most common cash-pay route for consumers. You choose the test online, pay the service, receive a lab requisition authorized through the service’s clinician network, and go to a participating collection site for a blood draw. Results are then posted through the ordering platform, the lab portal, or both.

The advantages are transparent up-front pricing, no separate office visit solely to request the test, and access to national collection networks. The tradeoffs are state restrictions, limited ability to integrate results into your medical record, and the need to arrange follow-up interpretation if the result is positive or unexpected.

2. Your clinician orders the test through Quest or Labcorp

If you already have a clinician managing a clotting, pregnancy, surgery, or hormone-related question, a clinician-ordered test may be the better route. It can help ensure the right test is selected, related tests are timed correctly, and results are interpreted with your personal risk factors.

Labcorp lists Factor II (Prothrombin), DNA Analysis as test 511162. Quest lists prothrombin Factor II 20210G>A mutation analysis in its thrombosis testing materials as test 17909. These menus generally do not provide a universal consumer cash price because the final cost depends on payer contracts, self-pay estimate rules, location, and where the order is placed.

3. Broader thrombophilia panels

Some people compare a single prothrombin mutation test with a panel that also includes factor V Leiden, protein C, protein S, antithrombin, lupus anticoagulant testing, anticardiolipin antibodies, beta-2 glycoprotein antibodies, or other markers. Panels can be appropriate when a clinician is evaluating a specific VTE history, but they are more expensive and some components are affected by acute thrombosis, pregnancy, anticoagulants, inflammation, or timing. Self-ordering a broad panel without a plan for interpretation can create confusing results and extra costs.

State restrictions and availability

Consumer-initiated lab testing is regulated state by state. Some online services cannot sell or fulfill certain lab orders in states such as New York, New Jersey, Rhode Island, Maryland, or Massachusetts depending on the lab network and physician-order model. Quest’s consumer store says QuestHealth tests are not currently available in Arizona, Hawaii, or Puerto Rico, and some tests may have additional restrictions by state, age, or sex. See the QuestHealth help center. Private MD Labs states that laboratory testing is available in 46 states and that Hawaii is excluded because its prepaid requisitions use Quest or Labcorp patient service centers. See Private MD Labs state availability.

Because restrictions can change, do not rely only on a search result. Enter your state early in checkout before comparing prices. A lower advertised price is not useful if the provider cannot legally fulfill the order where you live.

Preparation, sample collection, and turnaround

Most prothrombin mutation tests require no fasting. For online self-pay blood draw orders, bring the requisition, a photo ID, and any instructions from the ordering service. The blood sample is commonly collected in an EDTA tube. Quest materials list 5 mL room-temperature whole blood in an EDTA lavender-top tube with a 3 mL minimum for test 17909. Labcorp lists whole blood or a Labcorp buccal swab kit as acceptable specimen types for its provider-ordered test 511162.

Anticoagulant medications such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or enoxaparin generally do not change an inherited DNA result. However, they can affect many other clotting tests. If you are having a broader thrombophilia evaluation, ask the ordering clinician whether any non-genetic tests should be delayed or interpreted with medication timing in mind.

Turnaround varies. Ulta’s test page reports an average processing time of 4–5 business days for the Quest-based test. Labcorp lists 5–7 days as the usual number of days from pickup to result release for its Factor II DNA Analysis. Quest-associated listings for test 17909 often show reports available in about 3–4 days from receipt at the performing laboratory. Shipping, holidays, specimen issues, confirmatory steps, and lab workload can extend those times.

How to interpret results

Reports usually state whether the F2 variant was detected and may include an interpretation. Common result categories include:

• Negative / no mutation detected: the common F2 G20210A variant was not found. This lowers the likelihood of prothrombin thrombophilia from that variant, but it does not rule out all inherited or acquired clotting risks.
• Heterozygous: one copy of the variant was detected. This is the most common positive result. It increases VTE susceptibility, but many heterozygous people never have a clot.
• Homozygous: two copies were detected. This is rare and generally associated with higher risk than heterozygosity.
• Compound risk: a person may have the prothrombin variant plus another thrombophilia, such as factor V Leiden. Labcorp’s test information notes that individuals with both an F2 c.*97G>A variant and factor V Leiden have substantially increased VTE risk compared with people without those variants.

A positive result is not an emergency by itself. It does not prove that leg pain, chest pain, shortness of breath, or swelling is caused by a clot. Those symptoms require timely medical evaluation regardless of genetic status. Conversely, a negative result does not make clotting impossible.

Result interpretation should consider personal history, family history, provoking factors, hormone exposure, pregnancy or postpartum status, surgery, immobilization, smoking, cancer, and other lab results. GeneReviews summarizes that factors predisposing to thrombosis include the number of F2 variant alleles, coexisting genetic or acquired thrombophilias, and circumstantial risk factors such as pregnancy and oral contraceptive use.

Limitations and practical cautions

The test is targeted

Most commercial prothrombin mutation tests check the common F2 c.*97G>A variant. They are not full sequencing of every possible F2 variant and do not evaluate all causes of thrombosis. Labcorp’s test menu states that its assay analyzes the c.*97G>A variant and that results must be combined with clinical information for the most accurate interpretation.

A DNA result does not predict if or when a clot will occur

Inherited thrombophilia is about risk, not certainty. A heterozygous result may influence prevention planning during high-risk periods, but it does not automatically mean lifelong anticoagulation is needed. Decisions about blood thinners depend on the full clinical picture and the reason testing was done.

Some testing may not be recommended

Testing asymptomatic minors is generally discouraged in many inherited thrombophilia situations because childhood VTE is uncommon and the result may not change management. The ACMG technical standard notes that testing is generally not recommended for asymptomatic minors. Adults should also ask what action would follow a positive or negative result before paying cash.

Genetic privacy deserves thought

In the United States, the Genetic Information Nondiscrimination Act protects against many uses of genetic information in health insurance and employment, but it does not cover life insurance, disability insurance, or long-term care insurance. The National Human Genome Research Institute explains these protections and gaps. If the result could affect future insurance planning, consider discussing timing and privacy questions before ordering.

Customer satisfaction evidence: how to read it

Public customer reviews can help you assess ordering convenience, result delivery, and support, but they should not be treated as proof of clinical quality for a specific genetic assay. Ulta’s public listing displays a 4.9/5 review average based on thousands of moderated reviews, and Trustpilot hosts additional Ulta Lab Tests reviews. Private MD Labs publishes customer stories and also has Trustpilot reviews. LabsMD has a Better Business Bureau profile that states it is not BBB accredited. These signals are useful for consumer experience, but test selection should still be based on the correct assay, lab network, total cost, availability, and the plan for result interpretation. See Ulta Lab Tests on Trustpilot, Private MD Labs on Trustpilot, and the LabsMD BBB profile.

Best next steps before you buy

1. Confirm the exact test: look for Factor II, F2, prothrombin G20210A, c.*97G>A, CPT 81240, or Quest 17909/Labcorp 511162.
2. Check the final price: include requisition, physician authorization, draw, processing, or platform fees.
3. Enter your state: confirm the provider can fulfill the order where you live.
4. Know how results will be reviewed: especially if you have had a clot, are pregnant or planning pregnancy, use estrogen therapy, or have a strong family history.
5. Avoid duplicate testing: if a clinician already ordered a thrombophilia panel, the prothrombin variant may already be included.

 

FAQs

How much does a prothrombin gene mutation test cost?

The lowest confirmed self-pay total found is about $181.90 for a Quest-based Prothrombin (Factor II) 20210G>A Mutation Analysis through Ulta Lab Tests, including the listed $168.95 test price plus a $12.95 requisition charge. Other self-pay listings may be several hundred dollars higher. Clinician-ordered pricing through Quest or Labcorp varies by payer, setting, and self-pay estimate.

Is a prothrombin gene mutation test worth it?

It can be worth it when the result would change a decision, such as anticoagulation duration, pregnancy or postpartum planning, estrogen-containing medication choices, surgery planning, or family counseling. It is less useful when ordered out of curiosity without a plan for interpretation or action.

Can I use insurance?

Possibly, but coverage depends on your plan, medical necessity criteria, diagnosis codes, and whether the lab is in network. A doctor-ordered test may be more likely to include documentation needed for coverage. If you use an online cash-pay service, you usually pay up front and may not be able to bill insurance directly.

Does a positive result mean I need blood thinners?

Not necessarily. Many people with one copy of the variant never develop a clot. Blood thinner decisions depend on clot history, recurrence risk, bleeding risk, pregnancy status, other thrombophilias, and current clinical circumstances.

Can blood thinners affect the result?

They generally do not affect this DNA result. Blood thinners can affect other coagulation tests, so medication timing matters more for broader thrombophilia panels than for a targeted F2 mutation test.

Should family members be tested?

Sometimes. Testing adult first-degree relatives may be considered when results would influence prevention during higher-risk periods, such as pregnancy, estrogen therapy, major surgery, or prolonged immobilization. Testing children without a near-term management reason is often not recommended.

What symptoms should not wait for genetic testing?

New one-sided leg swelling or pain, sudden shortness of breath, chest pain, coughing blood, fainting, or neurologic symptoms need urgent medical evaluation. Genetic testing is not a tool for diagnosing an active clot.

Sources

• GeneReviews: Prothrombin Thrombophilia
• MedlinePlus Genetics: Prothrombin thrombophilia
• ACMG technical standard: factor V Leiden and factor II c.*97G>A testing
• American Society of Hematology: thrombophilia testing guidelines
• Labcorp test 511162: Factor II (Prothrombin), DNA Analysis
• Quest Diagnostics bleeding and thrombosis test menu
• Ulta Lab Tests: Prothrombin (Factor II) 20210G>A Mutation Analysis
• FindLabTest: Quest 17909 self-pay comparison
• National Human Genome Research Institute: genetic discrimination and GINA